Board of Directors
Isa Odidi, Ph.D., MBA
Chairman, CEO, Co-Chief Scientific Officer (CSO)
In 1998, Dr. Isa Odidi co-founded Intellipharmaceutics Inc., the predecessor of publicly-traded Intellipharmaceutics International Inc. From 1995 to 1998, Dr. Odidi held positions, first as Director, then as Vice President of Research of Drug Development and New Technologies, at Biovail Corporation International, (now Valeant Pharmaceutical International, Inc.), a drug delivery company.
Prior to 1995, Dr. Odidi held several senior positions in academia and in the pharmaceutical and health care industries. His work has been cited in textbooks and he has published over a hundred scientific and medical papers, articles and textbooks.
Dr. Odidi currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada and is an Adjunct Professor at the Institute for Molecular Medicine in California.
Dr. Odidi holds a B.Sc. Pharmacy from Ahmadu Bello University, Nigeria, an M.Sc. Pharmaceutical Technology, Ph.D. Pharmaceutics from the University of London, and his MBA from Joseph L. Rotman School of Management, University of Toronto. He is also a graduate of the Western Executive Program, Ivey School of Business at the University of Western Ontario. Dr. Odidi was recently awarded an Honorary Doctor of Science degree (Honoris causa) from the University of Benin, Nigeria.
Amina Odidi, Ph.D.
President, COO, Co-Chief Scientific Officer (CSO)
In 1998, Dr. Amina Odidi co-founded Intellipharmaceutics Inc., the predecessor of publicly-traded Intellipharmaceutics International Inc. Dr. Odidi has been President, COO, and Co-Chief Scientist since 1998. She has extensive experience developing and applying proprietary technologies to the development of controlled-release drug products for third-party pharmaceutical companies. She has invented or co-invented various proprietary controlled delivery devices for the delivery of pharmaceutical, nutriceutical, biological, agricultural and chemical agents. In the past she has worked for the pharmaceutical and health care industry. Dr. Odidi has co-authored eight articles, papers and textbooks.
Dr. Odidi holds a B.Sc. in Pharmacy, an M.S. in Biopharmaceutics, and a Ph.D. in Pharmaceutics from the University of London.
Kenneth Keirstead has served as a director of Intellipharmaceutics Inc. since 2006. Mr. Keirstead is educated in clinical biochemistry and business administration. He has worked in the health care delivery and pharmaceutical industries for over 45 years. He was President and CEO of Sanofi Winthrop Canada Inc., General Manager of Squibb Medical Systems International, President of Chemfet International and President of Quinton Instruments, among other positions. He has published studies and reports on health care and related services. Since 1998, Mr. Keirstead's principal occupation has been Executive Manager of the Lyceum Group, a Canadian consulting services company primarily active in the health care field, of which he is the founder.
Bahadur Madhani, CM
Bahadur Madhani, an accountant by training, has been a director since March 31, 2006. Since 1983, Mr. Madhani's principal occupation has been President and CEO of Equiprop Management Limited, a Canadian property management company of which he is the principal shareholder. At present, he is also on the Board of the YMCA of Toronto and YMCA Canada. He was previously a member of the advisory board of Quebecor Ontario. He has also served as Chairman of United Way of Toronto, Chairman of the YMCA of greater Toronto, and Chairman of the Nelson Mandela Children's Fund of Canada. Mr. Madhani was awarded membership in the Order of Canada in 2001.
Norman M. Betts, PhD.